← Back to headlines
Truist Assigns Buy Rating to Genmab
Truist has issued a 'Buy' rating for Genmab (GMAB), signaling a positive investment outlook for the biotechnology company.
5 Jun, 16:36 — 5 Jun, 16:36
Sources
Showing 1 of 1 sources
Truist has issued a 'Buy' rating for Genmab (GMAB), signaling a positive investment outlook for the biotechnology company.
